详情页 - 首都医科大学附属北京同仁医院知识库

当前位置：首页 > 详情页

Overexpression of enolase 2 is associated with worsened prognosis and increased glycikolysis in papillary renal cell carcinoma.

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Department of Anesthesiology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. [2]Department of Urology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. [3]Department of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China. [4]Department of Urology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China. [5]Department of Anesthesiology, Jing'an District Central Hospital of Shanghai, Shanghai, China. [6]Department of Anesthesiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. [7]Department of Urology, Zhongshan Hospital Qingpu Branch, Fudan University, Shanghai, China.

出处：

DOI：

ISSN：

关键词： ENO2 glycolysis papillary renal cell carcinoma

摘要：

Papillary renal cell carcinoma (pRCC) is characterized with underlying genetic disorders and the role enolase 2 (ENO2) in ccRCC is unknown. An in silico exploratory analysis using multiple public genetic datasets was used to establish association between ENO2 expression and clinicopathological parameters. Associations of interest were validated using 49 pRCC samples using immunohistochemistry. In vitro and in vivo assays were carried out to validate findings in tissue. ENO2 was overexpressed and prognostic in pRCC. ENO2 expression was significantly higher in younger patients and in CpG island methylator phenotype subtype. ENO2-overexpressed cases showed significant enrichment in glycolysis. Overexpression of ENO2 significantly increased proliferation and silencing of ENO2 significantly inhibited growth of ACHN cells. Glycolytic genes HK1, HK 2, and lactate dehydrogenase A were decreased when ENO2 was silenced in ACHN. Glycolytic inhibitor TT-232 showed minimal inhibitory effect on ACHN cells yet showed synergistic effect in the presence of ENO2 silencing. ENO2 significantly increased and decreased extracellular glucose, respectively in ACHN cells. Xenograft mouse model showed ENO2 silencing and TT-232 combination treatment showed synergistic effect in ACHN tumors. ENO2 is associated with worsened prognosis in pRCC and is related to glycolysis. ENO2-targeted therapy can be of therapeutic potential.© 2020 Wiley Periodicals LLC.

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2019]版：

大类 | 2 区生物

小类 | 2 区生理学 3 区细胞生物学

最新[2025]版：

大类 | 3 区生物学

小类 | 3 区细胞生物学 3 区生理学

第一作者：

第一作者机构： [1]Department of Anesthesiology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

通讯作者：

通讯机构： [1]Department of Anesthesiology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. [*1]Department of Anesthesiology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, 200336 Shanghai, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Overexpression of enolase 2 is associated with worsened prognosis and increased glycikolysis in papillary renal cell carcinoma [2]乳头状肾细胞癌的影像学诊断价值 [3]ENO2 Promotes Cell Proliferation, Glycolysis, and Glucocorticoid-Resistance in Acute Lymphoblastic Leukemia [4]Agrimonolide inhibits glycolysis in ovarian cancer cells by regulating HIF1A [5]Long noncoding RNA NR_027340 promotes head and neck cancer cell proliferation and glycolysis via PFKP [6]Genistein suppresses aerobic glycolysis and induces hepatocellular carcinoma cell death [7]α-Hederin inhibited pancreatic cancer cell malignant progression by inhibiting LDHA-mediated glycolysis [8]β-Klotho promotes glycolysis and glucose-stimulated insulin secretion via GP130. [9]12-HEPE promotes cardiomyocyte proliferation by activating glycolysis and histone lactylation via Hippo signaling [10]Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma